- Overview―clinical study on the effectiveness of RE therapy for HIV infection/AIDS
Change in CD4/CD8 Ratio
Group RH
After 12 weeks of RE therapy and HAART, the mean CD4/CD8 ratio increased by 0.122 (p = 0.00155). Of the 20 subjects, CD4/CD8 ratio increased in 18 and decreased in 2.
Group H
After 12 weeks of HAART, the mean CD4/CD8 ratio decreased by 0.009 (p = 0.710). Of the 20 subjects, CD4/CD8 ratio increased in 9 and decreased in 11.
Group R
After 12 weeks of HAART, the mean CD4/CD8 ratio increased by 0.070 (p = 0.153). Of the 20 subjects, CD4/CD8 ratio increased in 6 and decreased in 4.
Group U
After 12 weeks in the untreated group, the mean CD4/CD8 ratio decreased by 0.045 (p = 0.156). Of the 10 subjects, CD4/CD8 ratio increased in 3 and decreased in 7.


Implication from the Above Outcomes
The above outcomes showed that combining HAART with RE therapy effectively increased CD4/CD8 ratio.